We carried out this study to evaluate the efficacy and adverse events of the regimen at K hospital. Subjects and methods: This is a descriptive study on 40 patients diagnosed with stage IV colorectal cancer without RAS / BRAF mutations at K hospital from July 2017 to August 2022 that were treated with Cetuximab combined with chemotherapy regimens of mFOLFOX6 or mFOLFIRI.